Glipizide film-controlled slow-release pellet capsule

Abstract

The invention relates to a glipizide film-controlled slow-release pellet capsule. A slow-release film of the glipizide film-controlled slow-release pellet utilizes Eurdragit RL 30D as a film-formation material. A pellet core of the glipizide film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose, lactose and sodium dodecyl sulfate, and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit RL 30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit RL 30D to triethyl citrate to talcum powder is 30: 3: 4 and a film weight increasing ratio is in a range of 17 to 36%. The glipizide film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the glipizide film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the glipizide film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

Description

technical field [0001] The invention relates to a glipizide membrane-controlled sustained-release pellet capsule, in particular to a glipizide membrane-controlled sustained-release pellet capsule whose pellet core contains sodium carboxymethyl starch, and belongs to the field of pharmaceutical preparations. Background technique [0002] Glipizide is an oral hypoglycemic drug of the sulfonylurea class, which can promote the secretion of insulin by pancreatic β cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic α cells to inhibit the secretion of glucagon, as well as inhibit glycogen Protolysis, promoting muscle utilization and consumption of glucose, for the treatment of type 2 diabetes. [0003] Glipizide is almost insoluble in water, and the earliest common preparation on the market needs to be taken 3 times a day, the blood concentration fluctuates greatly, the peak concentration is too high, and the adverse reactions are serious. ...

AI Technical Summary

Problems solved by technology

[0008] In order to solve the problem of release decline caused by membrane aging of glipizide membrane-controlled sustained-release pellets prepared by water dispersion coating, the present invention provides a membrane-controlled membrane-controlled pellet that can maintain stable release performance throughout the validity period. Type Glipizide Sustained-release Pellet Capsule Capsules, characterized in that the core of the pellets contains sodium carboxymethyl starch with high water-swellability, and the sustained-release coating film is deformed by water-absorbing swelling, thereby offsetting the film Ageing

Images